Our research focuses on substance use disorders in pregnancy and substance-exposed newborns. Specifically, we are conducting trials related to pharmacologic treatments for opioid use disorder in pregnancy, cannabis use disorders in pregnancy, placental biomarkers, genetics, pharmacokinetics, fetal alcohol spectrum disorders (FASD), and the long-term childhood outcomes of substance exposure in-utero.
See all of our pediatric research programs.
Contact
Principal Investigator
Elisha M. Wachman
Elisha.Wachman@bmc.org
Project Manager
Chloe Deflorimonte
Chloe.Deflorimonte@bmc.org
Investigators
Department of Pediatrics
Elisha M. Wachman, MD
Vincent C. Smith, MD, MPH
Mei Elansary, MD, MPhil
Mark Mirochnick, MD
Department of Obstetrics
Kelley Saia, MD
Erica Holland, MD
Research projects
- CTN-0080 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMS) Randomized Clinical Trial (UG1DA013732), NCT03918850
- MAT LINK (Maternal and Infant Network to Understand Outcomes Associated with Medication for Opioid Use Disorder in Pregnancy), https://www.cdc.gov/ncbddd/aboutus/mat-link.html
- Effects of Prenatal Opioid Exposure on Placental DNA Methylation and Gene Expression, March of Dimes Research Grant
- POD (Placental Markers of Opioid Use Disorder on Development) Study (R01HD113143)
- The First Year Study: A Prospective Mixed Methods Study of Maternal and Child Well-being and Risk of Relapse in the First Year Postpartum (BU CTSI)
- SAFEST choice: https://www.bmc.org/addiction/training-education/safest-choice
AAP FASD Toolkit: https://www.aap.org/en/patient-care/fetal-aclohol-spectrum-disorders/ - Naltrexone for Cannabis Use Disorder in Pregnancy (BU CTSI)